WallStSmart

Abbott Laboratories (ABT)vsCapsoVision, Inc. Common Stock (CV)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 332673% more annual revenue ($45.13B vs $13.56M). ABT leads profitability with a 13.9% profit margin vs -198.9%. ABT earns a higher WallStSmart Score of 54/100 (C-).

ABT

Buy

54

out of 100

Grade: C-

Growth: 4.0Profit: 6.0Value: 4.7Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

CV

Avoid

14

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 2/9Altman Z: -13.46
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-32.7%)

Margin of Safety

-32.7%

Fair Value

$70.91

Current Price

$92.71

$21.80 premium

UndervaluedFair: $70.91Overvalued

Intrinsic value data unavailable for CV.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT1 strengths · Avg: 9.0/10
Market CapQuality
$163.94B9/10

Large-cap with strong market position

CV1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0410/10

Conservative balance sheet, low leverage

Areas to Watch

ABT2 concerns · Avg: 3.0/10
P/E RatioValuation
26.4x4/10

Moderate valuation

EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

CV4 concerns · Avg: 3.8/10
Price/BookValuation
18.3x4/10

Trading at 18.3x book value

Revenue GrowthGrowth
0.3%4/10

0.3% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$375.73M3/10

Smaller company, higher risk/reward

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap. PEG of 1.40 suggests the stock is reasonably priced for its growth.

Bull Case : CV

The strongest argument for CV centers on Debt/Equity.

Bear Case : ABT

The primary concerns for ABT are P/E Ratio, EPS Growth.

Bear Case : CV

The primary concerns for CV are Price/Book, Revenue Growth, EPS Growth.

Key Dynamics to Monitor

ABT profiles as a value stock while CV is a turnaround play — different risk/reward profiles.

ABT is growing revenue faster at 7.8% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ABT scores higher overall (54/100 vs 14/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

CapsoVision, Inc. Common Stock

HEALTHCARE · MEDICAL DEVICES · USA

CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company is headquartered in Saratoga, California.

Visit Website →

Want to dig deeper into these stocks?